Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication,[6] administered intravenously.

Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States,[7] and in the European Union in January 2008.

This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.